Vaxcyte, Inc. (PCVX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$61.16-0.02%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PCVX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete enrollment and report topline safety, tolerability, and immunogenicity data from OPUS-1 in Q4 2026 and OPUS-2 and OPUS-3 in H1 2027 to support BLA submission and potential U.S. commercial la…
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and a recent 2026-09-03 release. Management expects topline data from OPUS-1 in Q4 2026 and OPUS-2 and OPUS-3 in H1 2027 to support BLA submission and potential launch. The timeline has been consistently maintained with a recent update narrowing OPUS-1 data timing to end of October 2026, indicating delivering progress on clinical milestones.
“Topline data from OPUS-1 expected in fourth quarter of 2026; OPUS-2 and OPUS-3 results expected in first half of 2027.”
“OPUS-1 topline readout expected in the fourth quarter; OPUS-2 and OPUS-3 results expected in first half of 2027.”
Complete enrollment and report topline safety, tolerability, and immunogenicity data from the VAX-31 infant Phase 2 dose-finding study by end of first half 2027.
Stated in 2 of last 2 quarters (2026-Q1 and 2026-Q2). Management completed enrollment in the infant Phase 2 study and expects topline data by end of first half 2027. This timeline has been consistently maintained, indicating delivering progress on this pediatric clinical program.
“Topline data from VAX-31 infant Phase 2 dose-finding study expected by end of first half of 2027.”
“Enrollment completed for VAX-31 infant Phase 2 dose-finding study; topline data expected by end of first half of 2027.”
Initiate Phase 1 adult clinical study for VAX-A1 vaccine candidate in mid-2026 and report topline safety and immunogenicity data in second half of 2027.
Stated in 3 quarters including 2026-Q1 and 2026-Q2 and a recent 2026-09-03 release. Management initiated the Phase 1 study in mid-2026 and expects topline data in second half of 2027. The initiation milestone has been achieved and the timeline for data remains on track, indicating delivering progress on early-stage pipeline advancement.
“Company initiated Phase 1 study evaluating VAX-A1; topline data expected in second half of 2027.”
“Company expects to initiate Phase 1 adult clinical study for VAX-A1 in mid-2026.”
Maintain a strong balance sheet with cash, cash equivalents and investments above $2.4 billion to fund clinical, manufacturing, and commercial-readiness milestones.
Stated as a priority in 3 quarters including 2025-Q4, 2026-Q1, and 2026-Q2. Cash, cash equivalents and investments were $2.44B at 2025-Q4, increased to $2.74B at 2026-Q1, then slightly declined to $2.51B at 2026-Q2. Management has maintained a strong cash position to support growth, with the trajectory showing a stable and strong balance sheet consistent with stated priorities.
“Cash, cash equivalents and investments were $2.5 billion as of June 30, 2026.”
“Cash, cash equivalents and investments were $2.7 billion as of March 31, 2026.”
“Cash, cash equivalents and investments were $2.4 billion as of December 31, 2025.”
Vaxcyte plans to initiate the VAX-31 Adult Pivotal, Non-Inferiority Study in December 2025 with topline data expected in 2026.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Over the trailing year it converted 2.19x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.